JPH04500314A - 動物の体細胞の粒子媒介形質転換 - Google Patents
動物の体細胞の粒子媒介形質転換Info
- Publication number
- JPH04500314A JPH04500314A JP2509250A JP50925090A JPH04500314A JP H04500314 A JPH04500314 A JP H04500314A JP 2509250 A JP2509250 A JP 2509250A JP 50925090 A JP50925090 A JP 50925090A JP H04500314 A JPH04500314 A JP H04500314A
- Authority
- JP
- Japan
- Prior art keywords
- animal
- cells
- organ
- cell
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 title claims description 95
- 239000002245 particle Substances 0.000 title claims description 60
- 210000001082 somatic cell Anatomy 0.000 title claims description 29
- 230000009466 transformation Effects 0.000 title description 45
- 230000001404 mediated effect Effects 0.000 title description 5
- 238000000034 method Methods 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 82
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 210000000056 organ Anatomy 0.000 claims description 32
- 230000002068 genetic effect Effects 0.000 claims description 25
- 108020004414 DNA Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 210000004102 animal cell Anatomy 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 19
- 210000002220 organoid Anatomy 0.000 claims description 18
- 210000004185 liver Anatomy 0.000 claims description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 13
- 239000010931 gold Substances 0.000 claims description 13
- 229910052737 gold Inorganic materials 0.000 claims description 13
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 230000001131 transforming effect Effects 0.000 claims description 11
- 210000001835 viscera Anatomy 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 239000001307 helium Substances 0.000 claims description 5
- 229910052734 helium Inorganic materials 0.000 claims description 5
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000012620 biological material Substances 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 238000011426 transformation method Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 238000007599 discharging Methods 0.000 claims 1
- 238000010891 electric arc Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000005075 mammary gland Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003990 capacitor Substances 0.000 description 3
- 230000010307 cell transformation Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000269350 Anura Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004293 human mammary gland Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 210000005132 reproductive cell Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229920002799 BoPET Polymers 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000006032 tissue transformation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
- C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Electromagnetism (AREA)
- Cell Biology (AREA)
- Sustainable Development (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (25)
- 1.動物の体細胞を遺伝的に形質転換する方法であって、該動物の細胞内で遺伝 子生成物を表現し得るように構築された外来遺伝子構造のコピーを、該動物の細 胞の寸法に比して極めて小さな寸法の高密度物質の担体粒子に被覆する工程と、 平坦なキャリヤシート上に該被覆担体粒子を層状に展開する工程と、 該キャリャシートを火花放電室に設置する工程と、隔置された一対の電極の端部 間に、該電極間のギャップを橋絡するように水滴を配置する工程と、 該動物細胞を該キャリヤシートの移動する方向に設置する工程と、 電弧が該電極間のギャップを橋絡するように、高電位電源の放電を開始し、該水 溜を蒸発させ、かつ該キャリヤシートを該動物細胞の方向に加速して、該キャリ ヤシートが該動物細胞を打撃するのを回避するが、該担体粒子を該動物細胞内に 侵入せしめ、該担体粒子が該動物細胞を打撃する力は、該電極に印加される該高 電位電源の電圧を調節することにより、該外来遺伝子構造が該動物細胞中に導入 され、一方で該細胞の損傷が最小限度となるように、調節可能であることを特徴 とする上記遺伝的形質転換法。
- 2.該外来遺伝子構造が蛋白をコードするDNA配列および該動物細胞内で該蛋 白を表現するのに有効な近接調節配列を含む請求の範囲第1項記載の方法。
- 3.該外来遺伝子構造が、該動物細胞内で負のRNAストランドを表現し、在来 の遺伝子の表現を阻止し、あるいは疾病の進行を阻止するのに有効なDNA配列 である請求の範囲第1項記載の方法。
- 4.該動物細胞が、該動物の体外で培養されたものである請求の範囲第1項記載 の方法。
- 5.該動物細胞が生きた動物中でインビボ状態にあり、かつ該生きた動物全体が 該キャリヤシートの移動方向に配置されている請求の範囲第1項記載の方法。
- 6.形質転換される該動物細胞が該動物の皮膚にある請求の範囲第5項記載の方 法。
- 7.保持スクリーンが該火花放電室と該動物細胞との間に配置されていて、該キ ャリヤシートが該動物細胞に向けて加速された後に該シートを保持する請求の範 囲第1項記載の方法。
- 8.更に、該放電を開始する工程に先立って、該火花放電室と該動物細胞との間 の領域にヘリウムガスを導入する工程を含む請求の範囲第1項記載の方法。
- 9.該担体粒子が1〜3μの金粒子である請求の範囲第1項記載の方法。
- 10.請求の範囲第1項記載の方法により形質転換されたヒト以外の動物の体細 胞。
- 11.請求の範囲第1項記載の方法により、幾分かの体細胞が形質転換されたヒ ト以外の動物。
- 12.外来生物物質を生きた動物の体細胞内に導入する方法であって、 該外来生物物質のコピーを、該動物の細胞の寸法に比して極めて小さな寸法の高 密度物質の担体粒子に被覆する工程と、水滴を介して印加される電位の放電によ り蒸発される該水滴の膨張力により該粒子を加速することのできる装置に該被覆 粒子を設置する工程と、 該装置を介して該放電を開始して、該被覆担体粒子を該動物の細胞に向けてまた は該細胞内に加速する工程を含むことを特徴とする上記方法。
- 13.該生物物質が遺伝構造である請求の範囲第12項記載の方法。
- 14.該遺伝構造がDNAである請求の範囲第13項記載の方法。
- 15.該遺伝構造がRNAである請求の範囲第13項記載の方法。
- 16.細胞の寸法に比して小さな金の粒子を含有する該細胞と、該細胞内で遺伝 子生成物を表現するのに有効なキメラ遺伝子表現構造とを含むヒト以外の動物。
- 17.動物の内部器官の体細胞を遺伝的に形質転換する方法であって、 外来遺伝子構造のコピーを、形質転換すべき細胞に比して小さな寸法の担体粒子 上に被覆する工程と、但し該外来遺伝子構造は該動物の細胞内で遺伝子生成物を 表現し得るように構成されており、 該動物の内部器官を外科的に露出する工程と、該被覆担体粒子を、該動物の露出 された器官内に物理的に加速する工程と、 該器官を所定の位置において、該動物を外科的に閉じる工程と、 を含む上記方法。
- 18.該担体粒子を加速する力が火花ギャップを横切る高電位電源の放電により 供給される請求の範囲第17項記載の方法。
- 19.該内部器官が肝臓である請求の範囲第17項記載の方法。
- 20.該内部器官が筋肉である請求の範囲第17項記載の方法。
- 21.培養中の類器官の形質転換法であって、異種遺伝子構造のコピーを、該形 質転換すべき細胞よりも小さな寸法の担体粒子上に被覆する工程と、値し該異種 遺伝子構造は該類器官の細胞中で遺伝子生成物を表現し得るように構成されてお り、 該被覆粒子を、ターゲットサイトに物理的に加速し得る装置上に該被覆粒子を配 置する工程と、 該類器官を該装置のターゲットサイトに配置する工程と、該担体粒子を、該装置 を使用して該類器官内に加速する工程と、を含む上記方法。
- 22.該類器官が哺乳動物の類器官である請求の範囲第21項記載の方法。
- 23.該類器官がヒトの類器官である請求の範囲第22項記載の方法。
- 24.該類器官由来の初代培養物または該類器官に再構成されたものをターゲッ ト細胞として使用する請求の範囲第21項記載の方法。
- 25.動物の体内に異種遺伝物質を導入する方法であって、該動物から組織サン プルを取り出し、該組織サンプルを類器官にまで培養し、請求の範囲第21項記 載の方法に従って該類器官を遺伝的に形質転換し、次いで該形質転換された類器 官を該動物の体内に戻すことを特徴とする上記方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37186989A | 1989-06-26 | 1989-06-26 | |
US371,869 | 1989-06-26 | ||
US49493390A | 1990-03-14 | 1990-03-14 | |
US494,933 | 1990-03-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000387953A Division JP2001213807A (ja) | 1989-06-26 | 2000-12-20 | 動物の体細胞の粒子媒介形質転換 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04500314A true JPH04500314A (ja) | 1992-01-23 |
JP3573454B2 JP3573454B2 (ja) | 2004-10-06 |
Family
ID=27005554
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50925090A Expired - Lifetime JP3573454B2 (ja) | 1989-06-26 | 1990-06-21 | 動物の体細胞の粒子媒介形質転換 |
JP2000387953A Withdrawn JP2001213807A (ja) | 1989-06-26 | 2000-12-20 | 動物の体細胞の粒子媒介形質転換 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000387953A Withdrawn JP2001213807A (ja) | 1989-06-26 | 2000-12-20 | 動物の体細胞の粒子媒介形質転換 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20020081739A1 (ja) |
EP (1) | EP0431135B1 (ja) |
JP (2) | JP3573454B2 (ja) |
AT (1) | ATE235558T1 (ja) |
AU (2) | AU5856790A (ja) |
CA (1) | CA2019676C (ja) |
DE (1) | DE69034053T2 (ja) |
DK (1) | DK0431135T3 (ja) |
ES (1) | ES2194834T3 (ja) |
WO (1) | WO1991000359A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0500799B1 (en) | 1989-11-16 | 1998-01-14 | Duke University | Particle mediated transformation of animal skin tissue cells |
US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
AU1663392A (en) * | 1991-03-06 | 1992-10-06 | Agracetus, Inc. | Particle mediated transformation of cotton |
CA2098498A1 (en) * | 1991-10-15 | 1993-04-16 | Ning-Sun Yang | Particle-mediated transformation of mammalian unattached cells |
WO1993008292A1 (en) * | 1991-10-16 | 1993-04-29 | Agracetus, Inc. | Particle-mediated transformation of animal somatic cells |
US5260191A (en) * | 1992-01-30 | 1993-11-09 | Agracetus, Inc. | Method for diagnosing tumors |
EP0584339A4 (en) * | 1992-03-04 | 1996-02-28 | Jon A Wolff | Method of delivering therapeutic substances to the brain |
DK0584348T3 (da) * | 1992-03-11 | 2005-09-19 | Powderject Vaccines Inc | Genetisk vaccine mod immundefektvirusser |
AU2146092A (en) * | 1992-05-28 | 1993-12-30 | Scientific Dimensions Usa, Inc. | Transgenic animal production with biolistically transformed spermatozoa |
EP0706576A1 (en) * | 1993-06-30 | 1996-04-17 | Dcv Biologics L.P. | A method for introducing a biological substance into a target |
GB2282139A (en) * | 1993-09-24 | 1995-03-29 | Univ Reading | Introducing DNA into the germ line of birds |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US7223739B1 (en) | 1995-06-07 | 2007-05-29 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
BE1010344A3 (fr) * | 1996-06-12 | 1998-06-02 | Solvay | Vaccin plasmidique contre le virus pseudorabique. |
WO1997023502A1 (fr) * | 1995-12-21 | 1997-07-03 | Solvay (Societe Anonyme) | Vaccin plasmidique contre le virus pseudorabique |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
AU5366099A (en) | 1998-08-20 | 2000-03-14 | Connaught Laboratories Limited | Nucleic acid molecules encoding inclusion membrane protein of (chlamydia) |
US6881723B1 (en) | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
ATE513913T1 (de) | 2000-05-10 | 2011-07-15 | Sanofi Pasteur Ltd | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
ES2285087T3 (es) * | 2002-01-25 | 2007-11-16 | Glaxo Group Limited | Formas farmaceuticas de adn. |
GB0201736D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | DNA dosage forms |
EP1356820A1 (en) | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA vaccine combined with an inducer of tumor cell apoptosis |
EP2411519B1 (en) | 2009-03-27 | 2015-07-22 | Institut National de la Santé et de la Recherche Médicale | Kanamycin antisense nucleic acid for the treatment of cancer |
WO2011154863A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
WO2020130106A1 (ja) * | 2018-12-20 | 2020-06-25 | 国立大学法人豊橋技術科学大学 | 電気穿孔装置及び外来物質導入細胞の製造方法 |
IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
AU2021329906A1 (en) | 2020-08-18 | 2023-04-27 | Enviro Metals, LLC | Metal refinement |
WO2024200831A1 (en) | 2023-03-30 | 2024-10-03 | Vivadju | Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
IL84459A (en) * | 1986-12-05 | 1993-07-08 | Agracetus | Apparatus and method for the injection of carrier particles carrying genetic material into living cells |
US5015580A (en) * | 1987-07-29 | 1991-05-14 | Agracetus | Particle-mediated transformation of soybean plants and lines |
US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
US5405779A (en) * | 1993-04-09 | 1995-04-11 | Agracetus, Inc. | Apparatus for genetic transformation |
US5506125A (en) * | 1993-12-22 | 1996-04-09 | Agracetus, Inc. | Gene delivery instrument with replaceable cartridges |
-
1990
- 1990-06-21 JP JP50925090A patent/JP3573454B2/ja not_active Expired - Lifetime
- 1990-06-21 AT AT90910074T patent/ATE235558T1/de not_active IP Right Cessation
- 1990-06-21 EP EP90910074A patent/EP0431135B1/en not_active Revoked
- 1990-06-21 DK DK90910074T patent/DK0431135T3/da active
- 1990-06-21 ES ES90910074T patent/ES2194834T3/es not_active Expired - Lifetime
- 1990-06-21 AU AU58567/90A patent/AU5856790A/en not_active Abandoned
- 1990-06-21 DE DE69034053T patent/DE69034053T2/de not_active Revoked
- 1990-06-21 WO PCT/US1990/003522 patent/WO1991000359A1/en active IP Right Grant
- 1990-06-22 CA CA002019676A patent/CA2019676C/en not_active Expired - Lifetime
-
1994
- 1994-03-18 AU AU57873/94A patent/AU679477B2/en not_active Expired
-
2000
- 2000-12-20 JP JP2000387953A patent/JP2001213807A/ja not_active Withdrawn
-
2001
- 2001-12-20 US US10/032,316 patent/US20020081739A1/en not_active Abandoned
-
2005
- 2005-03-23 US US11/086,657 patent/US20050216959A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU5856790A (en) | 1991-01-17 |
ATE235558T1 (de) | 2003-04-15 |
DK0431135T3 (da) | 2003-07-21 |
AU5787394A (en) | 1994-05-19 |
US20020081739A1 (en) | 2002-06-27 |
EP0431135B1 (en) | 2003-03-26 |
JP3573454B2 (ja) | 2004-10-06 |
CA2019676C (en) | 2005-08-09 |
DE69034053D1 (de) | 2003-04-30 |
DE69034053T2 (de) | 2003-12-04 |
JP2001213807A (ja) | 2001-08-07 |
WO1991000359A1 (en) | 1991-01-10 |
AU679477B2 (en) | 1997-07-03 |
ES2194834T3 (es) | 2003-12-01 |
US20050216959A1 (en) | 2005-09-29 |
EP0431135A1 (en) | 1991-06-12 |
CA2019676A1 (en) | 1990-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH04500314A (ja) | 動物の体細胞の粒子媒介形質転換 | |
JP5774657B2 (ja) | エレクトロポレーションを利用した哺乳類の遺伝子改変方法 | |
DE69227872T2 (de) | Partikel-auslösende transformation von baumwolle | |
US5466587A (en) | Method for introducing a biological substance into a target | |
KR20050088162A (ko) | 핵이식용 세포질 수용체로서의 불활성화 난모 세포 | |
US6563017B2 (en) | In vivo electroporation method for early stage embryo of chickens | |
KR19990044148A (ko) | 핵 이식을 위한 휴지기의 세포 모집단 | |
US20070107074A1 (en) | Porcine Nuclear Transfer | |
KOMAR | Parthenogenetic development of mouse eggs activated by heat-shock | |
WO2023143637A1 (zh) | 一种实用型类脑微器官的构建与应用 | |
EP1254951A1 (en) | Molecule transferring device, auxiliary for molecule transferring device, and molecule transferring method | |
JPH06503479A (ja) | 動物体細胞の粒子−媒介トランスフォーメーション | |
Shimada et al. | Comparison of ES cell fate in sandwiched aggregates and co‐cultured aggregates during blastocyst formation by monitored GFP expression | |
US20050084960A1 (en) | Differentiation of human embryonic stem cells in avian embryos | |
Bevan et al. | The production and applications of genetically modified skin cells | |
JP3631438B2 (ja) | 鳥類初期胚に外来遺伝子を導入する方法及びそれに用いる電極 | |
Naito et al. | Efficient transfection of chicken blastoderms in vivo by lipofection and electroporation using green fluorescent protein gene as a marker | |
KR20090115081A (ko) | 개과 동물의 복제 생산 방법 | |
RU2094464C1 (ru) | Способ введения экзогенной днк плазмид в клетки млекопитающих, культивируемые in vitro | |
JPH07509217A (ja) | 治療物質を脳に送出する方法 | |
WO2003054151A2 (en) | Generation of transgenic mice by transgene-mediated rescue of spermatogenesis | |
JP2005525098A (ja) | ウサギの核クローニング方法並びにその用法 | |
Yang et al. | Particle bombardment for gene transfer into nerve cell systems | |
JPS6394979A (ja) | マメ科植物細胞への遺伝物質の導入方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040519 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040629 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070709 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080709 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080709 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090709 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090709 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100709 Year of fee payment: 6 |
|
EXPY | Cancellation because of completion of term |